Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 3, 2004, Pages 647-652

  Isonishi, Seiji ^a   Niimi, Shigeki ^a   Sasaki, Hiroshi ^a   Ochiai, Kazunori ^a   Yasuda, Makoto ^a   Tanaka, Tadao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced ovarian cancer; Chemotherapy; Cytoreductive surgery; Drug resistance; Drug sensitivity; Lymphadenectomy; Systematic lymphadenectomy

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IRINOTECAN; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DRUG SENSITIVITY; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 2942696402     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.006     Document Type: Article

References (15)

1. Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer. 71(Suppl. 4):1993;1534-1540
2. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 1(20):2002;1248-1259
3. Burghart E., Pickel H., Stettner H. Management of advanced ovarian cancer. Eur. J. Gynaecol. Oncol. 3:1984;155-159
4. Di Re F., Fontanelli R., Raspagliesi F., Di Re E. Pelvic and paraaortic lymphadenectomy in cancer of the ovary. Burghart E., Monaghan J.M. Clinical Obstetrics and Gynecology. vol. 3:1989;131-142 Bailliere Tindall, London
5. Di Re F., Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int. J. Gynecol. Cancer. 10:2000;435-442
6. Heintz A.P.M., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67:1986;738-748
7. Burghart E., Pickel H., Lahousen M., Stettner H. Pelvic lymphadenectomy operative treatment of ovarian cancer. Am. J. Obstet. Gynecol. 155:1986;315-319
8. Tulusan A.H., Adam R., Reinhard M., Atanasov N., Thyselius D., Merkle E., et al. Lymph node metastasis in epithelial ovarian cancer. Sharp F., Mason W.P., Leake R.E. Ovarian cancer: biological and therapeutic challenges. 1990;443-445 Chapman & Hall, London
9. Ozols R.F., Thigpen J.T., Dauplat J., Colombo N., Piccart M.J., Bertelsen K., et al. Advanced ovarian cancer. Dose intensity. Ann. Oncol. 4:1993;49-56
10. Shapiro J.D., Rothenberg M.L., Sarosy G.A., Steinberg S.M., Adamo D.O., Reed E., et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer. 83:1998;1980-1988
11. World Health Organization WHO handbook for reporting results of cancer treatment. 1979;World Health Organization, Geneva, Switzerland
12. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGure W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J. Clin. Oncol. 14:1996;1545-1551
13. Kaplan Z.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481
14. Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol. Oncol. 56:1995;328-337
15. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6